VHL is involved in a complex functional network that is important for tumor suppression. [11] Faulty genes within the network can act synergistically to induce tumors and the network can result in a cascade effect that affects tumor suppression by activating and inhibiting downstream genes. Burnichon et al [12] found that the succinate dehydrogenase x family and VHL act synergistically in the development of the pheochromocytoma. Similarly, Gimelli et al [13] found that haploinsufficiency of ring finger protein 139 (RNF139) might facilitate the development of clear-cell RCC in association with VHL mutations.
Clinically, VHL disease can be classified into four subtypes based on the presence of pheochromocytoma and/or RCC. Type I VHL is not associated with pheochromocytoma, and type II is associated with both hemangioblastoma and pheochromocytoma, with either a relatively low incidence (Type IIA) or a high incidence (Type IIB) of RCC and pancreatic tumors. In contrast, VHL IIC is characterized by a pheochromocytoma-only phenotype. [14, 15] Currently, based on the analysis of more than 300 families afflicted with VHL disease, more than 823 distinct mutations have been detected and registered in the Universal VHL-Mutation Database. [16] To date, a limited number of studies of VHL disease have been conducted in China. In the present study, we describe a five-generation VHL family from Northwestern China and present clinical and genetic analyses of VHL within this family. Moreover, we summarize the VHL mutations and clinical characteristics of Chinese families with VHL according to previous studies.
Methods

Patients
The Chinese family study included five-generations comprising of 38 living family members, of whom nine were affected [ Figure 1 ]. All living members were examined clinically. The clinical and radiographic images were published with the consent of the patient. The study was approved by the research Ethics Committees of Xi'an Jiaotong University School of Medicine. Written informed consents were obtained from all participants.
Epidemiological investigation of the family afflicted with Von Hippel-Lindau
Family members were interviewed to collect socio-demographic information that included age, gender, locality, education, income, and occupation. Blood pressure and ultrasound data were collected during the initial screening, and additional examinations were performed on the affected subjects at Shaanxi Sengong Hospital. The medical charts of the VHL-patients were reviewed, and relevant social and clinical data (e.g. biochemical tests, images, pathologic reports, etc.) were collected.
Genetic linkage and haplotype analyses
Peripheral blood leukocytes were collected from 33 of the 38 living family members, and human genomic DNA was extracted using the DNA Isolation Kit for Mammalian Blood (Tiangen Biotech Co., Ltd., Beijing, China). We genotyped three polymorphic microsatellite markers that flanked VHL on chromosome 3p25 (D3S3691, D3S1597 and D3S1263). The microsatellite markers were amplified by PCR using fluorescently labeled primers. The products were analyzed with an Applied Biosystems 3730 Genetic Analyzer (Applied Biosystem, Foster City, CA, USA). LOD scores were calculated using the MLINK program of the LINKAGE package 5.1 (Perkin Elmer, Waltham, USA). The parameters used for linkage analysis were autosomal dominant inheritance, complete penetrance, a mutation rate of 0, equal male-female recombination rates, equal allele frequency, and the disease allele frequency of 1 in 10,000. [17] Von Hippel-Lindau sequence analysis Mutation screening was performed by directly analyzing the DNA sequence output. The exons of VHL were amplified with primers flanking the exon-intron boundaries [ Table 1 ]. The PCR thermal cycling program was as follows: One cycle of 2 minutes for denaturation at 95°C, 35 cycles for 30 seconds at 95°C, 35 seconds at 57°C, 45 seconds at 72°C, and one 7 minutes extension step at 72°C. The PCR products were sequenced on an Applied Biosystems 3730 Genetic Analyzer. [17, 18] Summary of the mutations in the Chinese families with Von Hippel-Lindau disease
We searched for studies in PubMed (http://www.ncbi.nlm. nih.gov/sites/entrez?db = pubmed) using the following terms: "VHL," "Mutation" and "Chinese." All of the analyzed data have previously been published. [3] results
Clinical analysis
The proband in the family was a 42-year-old female [ Figure 1 : IV-3] who was first admitted to The First Affiliated Hospital of Xi'an Jiaotong University with a 2-week history of right upper abdomen pain in August 2011. An abdominal radiograph revealed neoplasms in the pancreas, bilateral adrenal gland, and spleen, bilateral renal cysts, cholecystolithiasis and pancreas atrophy with calcification [ Figure 2 ]. Based on the radiographic findings and the endocrinological results, a surgical treatment was performed. Ultimately, the histopathologic examination confirmed the diffuse PETs and the right pheochromocytoma.
A total of 38 living members (19 males and 19 females) of the family were identified, nine of these members (two males and seven females) were affected. The ages of the living family members ranged from 16 to 61 years (mean age: 32.20 ± 4.75 years). The onset ages of the living patients ranged from 20 to 40 years (mean age: 29.11 ± 5.74 years). In the nine affected subjects, there were three cases of HBs, two cases of PETs, three cases of pancreatic cysts, four cases of renal cysts, eight cases of pheochromocytomas (including four hemi-and four bilateral cases), and two cases of paragangliomas. Patient III-4 had a combination of HBs and pheochromocytoma, IV-7 exhibited HBs, pancreatic cysts, renal cysts and pheochromocytoma; IV-10 exhibited HBs and renal cysts; IV-3 and IV-5 exhibited combined pancreatic lesions (PETs and cysts), renal cysts, pheochromocytomas and paragangliomas, III-8, and IV-11, IV-15 and IV-20 suffered only from pheochromocytomas. Blood pressures above 140/90 were observed in 13 members, of whom six were also diagnosed with pheochromocytomas. The relevant imaging, social, and clinical data of the proband and the affected relatives were shown in Figure 2 , Tables 2 and 3 .
Linkage and haplotype analyses
We performed linkage analysis using three markers that spanned VHL. A maximal LOD score of 8.26 was obtained for marker D3S1263 at θ = 0.00, which suggested linkage [ Table 4 ]. Haplotype analysis revealed that haplotype 3-1-3 cosegregated with the disease in this family, 
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VHL disease is an autosomal dominant familial neoplasm syndrome caused by mutations in VHL that can lead to the development of tumors and cysts in multiple organs. In our study, we identified a functional C>T transition mutation (c. 499 C>T, p.R167 W) in the VHL gene in a North-western Chinese family suffering from VHL disease by linkage and sequencing analyses. A high maximal-LOD-score of 8.26 (θ =0.0) for the marker D3S1263 was obtained through the linkage analysis. The p.R167W mutation resulted in the substitution of arginine at position 167 with a tryptophan residue that co-segregated only in affected individuals. This mutation was only present in the affected VHL patients and was completely absent from the other healthy family members and an additional 100 healthy controls. The results of this research firmly indicated that the p.R167W mutation of VHL caused the disease in this family. According to the diagnostic and classification criterion, one patient were classified as Type I, four as Type IIA, and four as Type IIC. To our knowledge, there are very few studies of PETs in the world, and this is the first such report in China.
Mutations in VHL that result in amino acid changes between codons 157-189 tend to be associated with increases in the which indicated that the disease locus was linked to the chromosome region harboring VHL, and hence, indicated VHL as a candidate gene [ Figure 1 ].
Mutation analysis
A functional C>T transition mutation located within exon 3 of VHL (c. 499 C>T, p.R167W) was identified by mutation screening. This alteration was observed only in the affected members of the family and was not detected in any of the unaffected family members [ Figure 3 ]. Moreover, this nucleotide substitution was not found in 100 healthy control individuals (200 alleles), which indicated that this alteration was not a polymorphic variant of VHL.
Summary of the studies of Von Hippel-Lindau mutations in afflicted Chinese families
Currently, nine studies including the present study have been conducted on 77 Chinese families and have described 49 mutations of VHL. [19] [20] [21] [22] [23] [24] [25] [26] [27] The mutations were summarized according to the position, nucleotide change, effect on coding sequence, and associated VHL phenotype (s) [ Table 5 ]. Independent of phenotype, the most frequent mutations were severity of tumors. The mutation presented in this study occurred at codon position 167, which is critical to the normal functioning of VHL. [28, 29] Notably, the p.R167W mutation was found in four VHL phenotypes. Therefore, further examination of this codon might provide key insight into the function of VHL. Previous research conducted by Neumann et al. [30] reported that germline mutations of codon 167 convey a high risk for the development of pheochromocytoma. Moreover, the codon 167 mutation is correlated with the pheochromocytoma coalition with PETs. Zbar et al. [16] found the mutant VHL alleles that are associated with the subtypes that are characterized by pheochromocytoma with (p.R167Q and p.Rl67W) or without renal carcinoma (p.Y98H and p.Y112H). However, in the family we studied, the p.Rl67W mutation was connected to the pheochromocytoma without renal carcinoma phenotype. This discrepancy might be due to genetic heterogeneity between the two different ethnic populations. In China, there were reports of associations of p.Rl67W with each subtype of VHL. [23, 24] To the best of our knowledge, the first reported the association of p.R167W with Type II VHL in a family of Chinese origin.
The p.Rl67W mutation resulted in a change from arginine to tryptophan at position 167. The isoelectric point of tryptophan is 10.76, while that of arginine is 5.89 isoelectric. The isoelectric point is an important factor in the formation of the three-dimensional structures of proteins. Moreover, the benzene ring structure of tryptophan can affect the secondary and three-dimensional structure of proteins, and indeed, replacement of residues by tryptophan in other polypeptides has been associated with various diseases. [31] [32] [33] Indeed the p.VHL is the component of the VHL-Elongin BC-CUL2 (VCB) complex that acts as an ubiquitin-ligase E3 and directs proteasome-dependent degradation of HIF-1α. Interesting, the regional residues (p. 157-166) are involved in the interaction with the Elongin BC complex. Thus, the p.Rl67W mutation might affect the VCB complex by impeding binding to the Elongin BC complex. [28, 34] Our summary of the numbers of VHL mutations that have been reported in various Chinese families revealed that these numbers are substantially lower than the numbers of mutations that have been reported in populations of European origin. The most frequent mutations in China are p.S65W, p.N78S, p.R161Q and p.R167W, and the most frequent mutations in Western countries are p.F76del, p.N78S, p.Rl61Stop, p.R167Q, p.R167W and p.L178P. The most common VHL phenotype was Type I (40 mutations), and 11 mutations were associated with Type II (40:11). Zbar et al [16] also showed that 208 mutations were associated with Type I, and 66 mutations were associated with Type II (208:66). The reason for these differences might be related to genetic Items  III -4  III -8  IV -3  IV -5  IV -7  IV -10  IV -11  IV -15  IV - IIA  IIC  IIA  IIA  IIA  I  IIC  IIC  IIC function of VHL might be similar to other check-point proteins in that when mutations are present, uncontrolled cell proliferation (or more precisely, neoplasias) arise in various tissues. Further research is needed to clarify the molecular mechanisms of VHL's role in organ-specific tumors. [20] Siu et al. 2011 [23] Exon 3 c. 481C > A p.R161R I Wu et al. 2012 [22] Exon 3 c. 482G > A p.R161Q IIC Siu et al. 2011 [23] Tong et al. 2009 [27] Wu et al. 2012 [22] Exon 3 c. 484T > C p. [20] Exon 3 c. 499C > T p.R167W I, IIA, IIB, IIC
Siu et al. 2011 [23] Wu et al. 2012 [22] Exon 3 c. 500G > A p.R167Q I Zhou et al. 2010 [21] Exon 3 c. 503G > C p.S168T I Mao et al. 2009 [25] Exon 3 c. 529A > T p.R177X I Zhou et al. 2010 [21] Exon 3 c. 533A > T p.L178R I Zhou et al. 2010 [21] Exon 3 Exon 3 deletion I Zhang et al. 2008 [20] Exon 3 c. 642 + 70C > A (in 3-untranslated region causing nontypical disease) I Wu et al. 2012 [22] Intron 1 c. 340 + 1G > A Splice mutation I Zhou et al. 2010 [21] Intron 1 c. 340 + 5G > C Splice mutation IIB Huang et al. 2012 [19] Zhou et al. 2010 [21] Intron 1 IVS1 -38C > T Unknown I Zhang et al. 2008 [20] Intron 2 c. 463 + 1G > T splice mutation I Siu et al. 2011 [23] Complete deletion I Zhang et al. 2008 [20] A: Alanine; R: Arginine; N: Asparagine; C: Cysteine; Q: Glutamine; E: Glutamic acid; G: Glycine; H: Histidine; I: Isoleucine; L: Leucine; F: Phenylalanine; P: Proline; S: Serine; T: Threonine; W: Tryptophan; Y: Tyrosine; V: Valine; VHL: Von Hippel-Lindau. [19] Zhang et al. 2008 [20] Exon 1 c. 194C > G p.S65W I Zhang et al. 2008 [20] Zhou et al. 2010 [21] Wu et al. 2012 [22] Exon [20] Siu et al. 2011 [23] Huang et al. 2004 [24] Exon 1 c. 233A > C p.N78T I Zhang et al. 2008 [20] Exon 1 c. 239G > T p.S80I IIB Zhou et al. 2010 [21] Mao et al. 2009 [25] Exon 1 c. 257C > T p.P86S IIB Wu et al. 2012 [22] Exon 1 c. 257C > T p.P86L I Zhang et al. 2008 [20] Exon 1 c. 263G > A p.W88X I Wu et al. 2012 [22] Exon 1 c. 265C > T p.L89S I Zhang et al. 2008 [20] Exon 1 c. 269A > T p.N90I I Wu et al. 2012 [22] Exon 1 c. 280G > T p.E94X I Wu et al. 2012 [22] Exon 1 c. 286C > T p.Q96X I Zhang et al. 2008 [20] Exon 1 c. 293A > G p.Y98C IIA Zhang et al. 2008 [20] Exon 1 c. 319C > G p.R107G I Siu et al. 2011 [23] Exon 1 c. 332G > A p.S111N I Zhang et al. 2008 [20] Exon 2 Exon 2 deletion I Siu et al. 2011 [23] Exon 2 c. 344G > C p.H115R I Zhou et al. 2007 [26] Exon 2 c. 346G > C p.V116L I Mao et al. 2009 [25] Exon 2 c. 351G > A p.W117X I Zhang et al. 2008 [20] Exon 2 c. 374A > C p.H125P IIC Wu et al. 2012 [22] Exon 2 c. 388G > T p.V130F IIB Zhou et al. 2010 [23] Exon 2 c. 432G insertion Frameshift I Huang et al. 2012 [19] Contd... differences between the populations or might be due to differences in the efficiency of the dissemination of case reports. More precisely, the tracking and management of families with genetic diseases in China might be sub-par compare to European countries. For example, there were many case reports written in Chinese, but thorough studies of the entire family have not been subsequently performed. An effective registration and follow-up system are urgently needed to allow for the description and proactively treatment of Chinese families with VHL.
In summary, the present study identified a functional C>T transition mutation (c. 499 C>T, p.R167W) located within exon 3 of VHL that is likely the cause of VHL disease in this family. VHL mutations suggest that the
